South Rampart Pharma

South Rampart Pharma is a private, clinical-stage biotech pioneering a new class of safer pain therapeutics. Its core innovation lies in small molecules designed to bypass the liver and kidney toxicity of standard analgesics while eliminating opioid-like abuse potential. The lead candidate, SRP-001, has completed a Phase 1 trial demonstrating safety and robust pharmacokinetics, with plans for Phase 2 studies in acute, chronic, and neuropathic pain indications. The company operates with a lean model and is advancing a pipeline that includes oral, intravenous, and topical formulations of its proprietary compounds.

Proprietary small molecule platform designed to create non-opioid, non-NSAID analgesics that bypass metabolic pathways causing liver and kidney toxicity, and lack abuse potential.

The non-opioid pain market is highly competitive, with numerous biopharma companies exploring diverse mechanisms (e.g., NaV1.7/1.8 inhibitors, NGF antibodies, novel receptor agonists). South Rampart's differentiation hinges on proving a superior organ-sparing safety profile compared to existing standard-of-care small molecules like acetaminophen and NSAIDs.